ABSTRACT
ObjectiveIt remains an open question of whether the human-derived RUNX-related transcription factor 1 (RUNX1) influences the development of renal cell carcinoma. This study aims to investigate the expression and biological function of the RUNX1 gene in renal cell carcinoma.MethodsBioinformatics technique of gene chip was used to identify the expression of RUNX1 in renal cancer. The expression level of RUNX1 in renal cancer tissue was determined by real-time polymerase chain reaction (RT-PCR). Twenty samples of cancer tissue were collected from the Department of Urology, Affiliated Hospital of Nantong University between January 2015 and June 2019. Accordingly, the adjacent normal tissue of the tumor was as well collected. The 786-O cell line was transfected using small interfering RNA, and was subsequently divided into three groups by knocking down the RUNX1 gene: siRNA1 group (siRNA1 sequence transfected with si-RUNX1), siRNA2 group (siRNA2 sequence transfected with si-RUNX1), siRNA3 Group (siRNA3 sequence transfected with si-RUNX1), control group (control sequence empty vector siRNA transfection). Cell clone formation experiment was used to count the number of cell clone formation; MTT assay was used to detect 786-O cell proliferation activity; the Transwell tumor cell invasion experiment was used to analyze the amount of cell migration; Western blot was used to detect changes in protein levels.Results The expression of RUNX1 in renal tumor tissue was significantly higher than that in adjacent normal tissue. The expression of RUNX1 in renal tumor tissues was increased with the escalation of the malignant degree of the pathological stage. The prognosis of patients with high expression of RUNX1 was significantly poor than that of the patients with low expression of RUNX1. The results of cell colony formation assay and MTT assay showed that the cell viability and proliferation of si-RUNX1 groups were significantly inhibited compared to the control group (P<0.01 for both). Transwell assay showed that the number of 786-O cells passing through the membrane in the si-RUNX1 group (98.67±3.53/field) was significantly lower than that of the control group (143.3±8.74/field) (P<0.01).ConclusionThe expression of RUNX1 is correlated with the proliferation and migration ability of renal cancer cells. Knockdown of RUNX1 expression can significantly inhibit the proliferation and migration of renal cancer cells, suggesting that RUNX1 plays an important role in the proliferation and metastasis of melanoma. Hence, the RUNX1 gene can be used as a potential clinical diagnosis and treatment target and prognostic marker for renal cancer.
ABSTRACT
<p><b>BACKGROUND</b>Her-2/neu gene overexpression has been found in several malignancies, and is associated with poor prognosis; while its role in the tumorigenesis and progression of prostate cancer (PCa) is still controversial. This study aimed to evaluate the prognostic value of Her-2/neu protein expression and clinicopathologic factors in antiandrogen-treated Chinese men with PCa for disease progression and PCa-specific death.</p><p><b>METHODS</b>Her-2/neu protein expression was determined using immunohistochemistry (IHC) in specimens collected from 124 prostate biopsies and transurethral resection of prostate (TURP) from seven prostate cancer patients.</p><p><b>RESULTS</b>Her-2/neu protein expression was 0, 1+, 2+, and 3+ in 40 (30.5%), 8 (6.1%), 67 (51.1%), and 16 (12.2%) cases, respectively. Her-2/neu protein expression showed significant correlation as judged by Gleason score (P = 0.049), clinical tumor-node-metastases (cTNM) stage (P = 0.018) and disease progression (P = 0.001), but did not correlate with prostate-specific antigen (PSA) (P = 0.126) or PCa-specific death (P = 0.585). PSA (P = 0.001), Gleason score (P = 0.017), cTNM (P = 0.000) and Her-2/neu protein expression (P = 0.001) had prognostic value for evaluating the progression of PCa in univariate analysis. In Kaplan-Meier plots, both Gleason score (P = 0.035) and cTNM (P = 0.013) correlated with PCa-specific death. In multivariate analysis, only cTNM was significant for both disease progression (P = 0.001) and PCa-specific death (P = 0.031).</p><p><b>CONCLUSIONS</b>Her-2/neu protein expression is significantly correlated with Gleason score, cTNM and disease progression, although it is not an independent predictor of disease progression and PCa-specific death. cTNM staging serves as an independent prognostic factor for disease progression and PCa-specific death.</p>
Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Disease Progression , Kaplan-Meier Estimate , Prognosis , Prostatic Neoplasms , Metabolism , Mortality , Pathology , Receptor, ErbB-2 , MetabolismABSTRACT
<p><b>OBJECTIVE</b>The progression of prostate cancer (PCa) after endocrine therapy varies widely in different PCa patients. This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.</p><p><b>METHODS</b>We reviewed the clinicopathological data of 116 cases of prostate cancer treated by endocrine therapy, analyzed the clinicopathological factors that influence the progression-free survival time of PCa patients using univariate (log-rank test) and multivariate Cox proportional hazard models, and investigated the correlation among these factors by Spearman rank correlation analysis.</p><p><b>RESULTS</b>In the stepwise Cox proportional hazard model, the independent prognostic factors for PCa progression after endocrine therapy were found to be Gleason score (P < 0.01) and clinical stages (P < 0.01). The hazard of PCa progression after endocrine therapy increased 2.126 times that of the baseline for each unit of increase in Gleason score, and 6.625 times for each unit of increase in the clinical stage. The pretreatment PSA level was correlated with both clinical stages (P < 0.01) and Gleason score (P < 0.01).</p><p><b>CONCLUSION</b>Clinical stages and Gleason score were important factors that influenced the progression-free survival time after endocrine therapy in this cohort of PCa patients.</p>